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One sentence summary: 
Siglec receptor activation by a nanoparticle functionalized with sialic acid reduces macrophage-driven 
inflammation via an IL-10 dependent mechanism. 
 
Abstract: 
Sepsis is the single most frequent cause of death in hospitalized patients and severe sepsis is a leading 
contributory factor to Acute Respiratory Distress Syndrome (ARDS). At present there is no effective 
treatment for these conditions and care is primarily supportive. Murine sialic acid-binding 
immunoglobulin-like lectin-E (Siglec-E) and its human orthologs Siglec-7 and -9 are immunomodulatory 
receptors found predominantly on hematopoietic cells. These receptors are important negative regulators 
of acute inflammatory responses and are potential targets for the treatment of sepsis and ARDS. In this 
study, we describe a Siglec targeting platform consisting of poly(lactic-co-glycolic acid) (PLGA) 
nanoparticles decorated with a natural Siglec ligand: di(α2→8) N-acetylneuraminic acid (α2,8 NANA-
NP). This nanoparticle induced enhanced oligomerization of the murine Siglec-E receptor on the surface 
of macrophages, unlike the free α2,8 NANA ligand. Furthermore, treatment of murine macrophages with 
these nanoparticles blocked the production of lipopolysaccharide (LPS)-induced inflammatory cytokines 
in a Siglec-E dependent manner. The nanoparticles were also therapeutically beneficial in vivo in both 
systemic and pulmonary murine models of inflammation. Moreover, we confirmed the anti-inflammatory 
effect of these nanoparticles on human monocytes and macrophages in vitro and in an ex vivo lung 
perfusion (EVLP) model of lung injury. We also established that IL-10 induced Siglec-E expression, and 
α2,8 NANA-NP augmented the expression of IL-10 further. Indeed, the effectiveness of the nanoparticle 
depended on IL-10. Collectively, these results demonstrated a therapeutic effect by targeting Siglec 
receptors in inflammatory conditions with a nanoparticle-based platform. 
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Introduction: 
Sepsis is the single most frequent cause of death in hospitalized patients. Recent statistics have estimated 
occurrence worldwide as higher than 19 million cases per year. Unfortunately, despite 8 million sepsis-
caused deaths annually, there is no effective treatment. Current treatments are supportive, and often 
ineffective, with survivors tending to show persistent critical illness (PCI), which presents as long-term 
organ dysfunction (1, 2). In addition, approximately 25% of patients with severe sepsis progress to 
develop Acute Respiratory Distress Syndrome (ARDS) (3) and mortality from ARDS is approximately 
25-30% (4). The excessive pro-inflammatory responses that contribute to organ dysfunction in sepsis are 
typically initiated and driven by the Toll-like receptors (TLRs), which recognize pathogen-derived 
constituents such as lipopolysaccharide (LPS), bacterial lipoproteins and non-methylated CpG DNA (5). 
Additionally, TLRs signal sterile inflammatory responses driven by damage-associated molecular patterns 
(DAMPs). 
 
Sialic acid-binding immunoglobulin-like lectins (Siglecs) were originally identified as cell-surface 
transmembrane receptors found primarily on hematopoietic cells and are capable of inhibiting TLR 
signaling (6). Hence, Siglecs have attracted attention as diagnostic and therapeutic biomarkers in various 
diseases including acute myeloid leukemia, lymphoma, rheumatological disease and allergy (7-9). One 
member of this family, Siglec-E (and its human orthologues Siglec-7 and -9) is predominantly found on 
macrophages and neutrophils. Siglec-E is an important regulator of neutrophil infiltration during 
pulmonary inflammation (10) and is capable of abrogating TLR-mediated responses through tyrosine 
specific Src homology-2 domain-containing phosphatase-2 (SHP-2) recruitment (11). Likewise, the 
human ortholog Siglec-7 is present on various immune cell subsets and recruits SHP-1 upon activation to 
downregulate inflammatory mediators (12, 13).  
 
The natural ligands for Siglecs are sialic acids, which are derivatives of N-acetylneuraminic acid (NANA), 
a monosaccharide with a nine-carbon backbone that can be linked to other sugars generating considerable 
diversity (14). Importantly, sialic acids act as signaling molecules, activating Siglecs expressed on the 
surface of immune cells both in cis and in trans to initiate inhibitory signal transduction. Recognition of 
sialic acids by the Siglecs is particularly dependent on the point-to-point saccharide linkage (α2→3, 
α2→6 and α2→8) with different Siglec receptors having various binding preferences (15). We therefore 
have examined the therapeutic potential of targeting Siglecs in models of acute inflammation. Previous 
studies by ourselves (16) and others (17) have utilized complexed antibody strategies to engage Siglec 
receptors. However, the ability of bivalent antibodies to oligomerize receptors in vivo translates poorly to 
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patients (18). As an alternative approach, we here specifically target and activate Siglec receptors using a 
sialylated nanoparticle.  
 
Results: 
α2,8 NANA-NP target Siglec-E on macrophages to limit LPS-driven pro-inflammatory cytokine 
production in vitro. 
Biodegradable and biocompatible 150-nm poly(lactic-co-glycolic acid) (PLGA) nanoparticles were 
prepared with a salting out formulation method (19) and decorated with α2,8 NANA (α2,8 NANA-NP), 
prior to physicochemical characterization (Fig. S1). The capacity of α2,8 NANA-NP to elicit anti-
inflammatory effects was then evaluated in peritoneal macrophages stimulated for 12hr with LPS ± α2,8 
NANA-NP or associated controls. Exposure of macrophages to α2,8 NANA-NP significantly attenuated 
LPS-induced production of the pro-inflammatory cytokines TNF-α and IL-6 (Fig. 1A and 1B). These 
reductions were specifically attributed to the surface-display of α2,8 NANA because a series of controls 
did not produce similar anti-inflammatory effects: These included free α2,8 NANA alone, non-
functionalized nanoparticles (Nude-NP) or nanoparticles decorated with glucosamine (Glucosamine NP). 
Furthermore, the anti-inflammatory effects depended on both the dose and on surface density of α2,8 
NANA, with increasing sialic acid concentrations [1.4 to 15 µg] eliciting greater inhibitory effects. 
Moreover, the inhibitory effects of a single treatment of α2,8 NANA-NP were maintained for 24 hr, with 
minimal batch-to-batch variation (Fig. S1). 
 
Subsequently, we examined the specificity of the nanoparticle towards Siglec-E. Treatment of peritoneal 
macrophages with LPS induced Siglec-E mRNA and protein levels (Fig. 1C and 1D). LPS induction of 
Siglec-E was also shown in bone marrow-derived macrophages (BMDM) (Fig. 1E). Having demonstrated 
the presence of Siglec-E on LPS-stimulated macrophages, we sought to confirm that receptor engagement 
was required for the anti-inflammatory effects of these nanoparticles. In an initial experiment, we showed 
enhanced binding of α2,8 NANA-NP to recombinant Siglec-E Fc protein in vitro over non-functionalized 
control nanoparticles (Fig. S2). Next, the effects of the nanoparticles were determined in cells where 
surface Siglec-E had been pre-blocked with a non-agonistic antibody. This receptor blocking significantly 
impeded the anti-inflammatory capacity of α2,8 NANA-NP compared to controls (Fig. 1F). In order to 
conclusively rule out antibody cross-linking effects, Siglec-E was depleted in cells with RNA interference. 
Depletion of Siglec-E mRNA ablated the anti-inflammatory effects of α2,8 NANA-NP (Fig. 1G). The 
specificity of α2,8 NANA-NP for Siglec-E was further demonstrated by microscopy studies, in which 
increased adherence of the nanoparticle to macrophages was observed, upon surface-decoration with α2,8 
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NANA (Fig. 1H). This preferential binding of α2,8 NANA-NP was markedly reduced by pre-blocking 
with Siglec-E antibody (Fig. 1I). Finally, we investigated the clustering of Siglec-E on the plasma 
membrane of macrophages with fluorescent α2,8 NANA-NP (Fig. S2). Siglec-E localization was 
enhanced at areas of high α2,8 NANA-NP density compared with Nude-NP or Siglec-E non-agonistic 
antibody controls. This clustering was indicative of increased receptor activation (20, 21). Collectively, 
these data demonstrate that the anti-inflammatory effects of α2,8 NANA-NP towards murine 
macrophages occur via enhanced interactions with Siglec-E molecules, and are Siglec-E dependent.  
 
α2,8 NANA-NP attenuate inflammatory effects in murine models of systemic inflammation. 
The therapeutic potential of α2,8 NANA-NP in vivo was next examined in a mouse model of LPS-
induced systemic inflammation. Mice were challenged with an intraperitoneal (i.p.) injection of a lethal 
dose of LPS (6mg/kg) and treated with either α2,8 NANA-NP or Nude-NP i.p. at 0hr. In this lethal model 
7/8 animals treated with Nude-NP reached experimental endpoint within 32hr, while animals treated with 
α2,8 NANA-NP remained healthy (Fig. 2A). The survival benefits conferred by α2,8 NANA-NP 
corresponded with a significant reduction in serum TNF-α (Fig. 2B) and increased levels of IL-10 (Fig. 
2C). Having demonstrated that α2,8 NANA-NP could prophylactically prevent death in LPS-induced 
systemic inflammation, we next examined efficacy after the onset of inflammation (defined as a clinical 
score of 2: piloerection, huddling and diarrhea). α2,8 NANA-NP (2mg) or controls were administered at 
the peak of inflammation (2hr post-LPS), in accordance with previous reports (22). Similar to prophylactic 
treatment, α2,8 NANA-NP significantly enhanced survival (Fig. 2D) and analogous attenuation of serum 
TNF-α (Fig. 2E) and elevated IL-10 (Fig. 2F) were observed.  
 
As recent reports had indicated that Siglec-E was present on other innate immune cells, particularly 
neutrophils (10), we questioned whether the therapeutic effects of α2,8 NANA-NP were solely 
macrophage dependent in vivo. Therefore, mice were treated i.p. with clodronate liposomes to deplete 
macrophages (Fig. S3) (23) prior to administration of LPS and nanoparticles. No abnormal clinical signs 
were observed subsequent to depletion. However, the therapeutic benefit of α2,8 NANA-NP was lost in 
macrophage-depleted mice, with no significant difference in survival observed between Nude-NP and 
α2,8 NANA-NP groups (Fig. 2G). We also examined the binding of α2,8 NANA-NP to cell populations 
in peritoneal exudate. We observed that both macrophages (CD11b+F4/80+) and neutrophils 
(CD11b+Ly6G+) were Siglec-E-positive, although relative expression was greater on macrophages. This 
was reflected in greater binding of α2,8 NANA-NP by macrophages, whilst neutrophil binding was 
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negligible (Fig. S4). Taken together, these results indicated that α2,8 NANA-NP-mediated effects in vivo 
were a consequence of binding to Siglec-E expressed on macrophages. 
  
Thus far, the validation of α2,8 NANA-NP as a viable therapy was solely based on experimental models 
with LPS-driven inflammation. Therefore, the nanoparticles were next evaluated in the caecal ligation and 
puncture (CLP) model of polymicrobial sepsis. Inflammation in this model is driven by a multitude of 
TLR ligands and is much more clinically representative of sepsis and other acute inflammatory disorders 
(24, 25). Mice were anesthetized and CLP was performed as described previously (25). At 2hr post-
surgery and every 24hr subsequently, mice were treated with α2,8 NANA-NP, Nude-NP or associated 
controls. α2,8 NANA-NP markedly prolonged survival, while all other control animals failed to survive 
beyond 8 days (Fig. 2H). Moreover, while all groups initially developed clinical signs of sepsis, α2,8 
NANA-NP attenuated further progression of illness from day 2 onwards (Fig. 2I). These findings were 
also supported by core body temperature stabilization compared to controls (Fig. 2J). Collectively, these 
data suggest that α2,8 NANA-NP can produce therapeutic effects in a clinically relevant model of 
inflammation. 
 
α2,8 NANA-NP attenuate inflammatory effects in murine models of lung injury. 
Having established the efficacy of α2,8 NANA-NP in systemic inflammation and the CLP model of 
sepsis, the application of the nanoparticles in murine lung injury was next investigated. Intratracheal (i.t.) 
instillation of LPS in mice induces neutrophilic alveolitis and enhanced pro-inflammatory cytokine 
responses, features representative of the clinical features of ARDS (26-28). Following i.t. instillation of 
LPS, mice were administered 2mg α2,8 NANA-NP or Nude-NP i.p. 2hr post-endotoxin. Bronchoalveolar 
lavage (BAL) fluid neutrophilia was attenuated upon treatment with α2,8 NANA-NP, in comparison to 
mice that received Nude-NP (Fig. 3A). Conversely, macrophage numbers within total BAL cell 
populations were enhanced by α2,8 NANA-NP (Fig. 3B). Cytokine analyses also revealed that IL-10 
levels were significantly elevated following α2,8 NANA-NP administration (Fig. 3C). 
 
CLP has previously been employed to model pulmonary inflammation as a consequence of a systemic 
insult (29, 30). Therefore, the therapeutic efficacy of α2,8 NANA-NP was investigated in this indirect 
model of lung injury. At 6-8hr post-CLP, mice were treated i.t. with 20µg α2,8 NANA-NP or Nude-NP. 
Clinical scores were significantly lower after treatment with α2,8 NANA-NP (Fig. 3D), leading to a 
reduced mortality rate (Fig. 3E). These findings were consistent with the observed reductions in BAL fluid 
total cell counts (Fig. 3F) and neutrophil numbers (Fig. 3G). Collectively, these data suggest that α2,8 
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NANA-NP represent a viable therapeutic in murine models of lung injury using both i.p. and i.t. 
administration routes. 
 
IL-10 induced Siglec-E upregulation is potentiated by α2,8 NANA-NP. 
We next examined the mode of action of these potent anti-inflammatory nanoparticles. In previous murine 
studies, SHP-2 was recruited to the cytoplasmic domains of Siglec-E after receptor activation (11). 
Increased amounts of immunoprecipitated SHP-2 bound to Siglec-E were confirmed in cells treated with 
α2,8 NANA-NP, in comparison to Nude-NP-treated controls (lanes 4-6 vs. 7-9) (Figure 4A). Indicative of 
an anti-inflammatory response, α2,8 NANA-NP elevated Nuclear Factor Kappa B (NFκB) p50:p65 ratio 
within the nucleus (Fig. 4B). A key observation from our earlier data was that serum IL-10 was elevated 
in mice treated with α2,8 NANA-NP (Fig. 2C and 2F). However, the ability of α2,8 NANA-NP to 
enhance production of IL-10 was ablated in the absence of myeloid differentiation primary response gene 
88 (MyD88) (Fig. 4C) confirming previous reports that MyD88 was required for LPS-stimulated IL-10 
production (Fig. 4D) (31).  
 
Previous studies had indicated that Siglec-E expression is dependent upon MyD88 function (11). 
Therefore, we examined expression of Siglec-E induced by both LPS and IL-10 in more detail. Similar 
upregulation of both Siglec-E mRNA and protein was confirmed in peritoneal macrophages treated with 
either stimulus (Fig. 5A and 5B). In parallel studies, pre-blocking the IL-10 receptor resulted in marked 
ablation of Siglec-E levels on treatment with either LPS or IL-10 (Fig. 5C). Taken together, these data 
demonstrated that IL-10 regulated the expression of Siglec-E. We hypothesized that the effect of the 
nanoparticles would therefore be dependent on IL-10. This was confirmed using IL-10-/- mice, where 
administration of α2,8 NANA-NP was unable to rescue these animals from LPS-induced mortality (Fig. 
5D), nor reduce serum TNF-α in comparison to WT controls (Fig. 5E).   
 
α2,8 NANA-NP exhibit negligible toxicity in pre-clinical models. 
To analyze possible side-effects of α2,8 NANA-NP, we also assessed indicators of toxicity. To mimic the 
treatment regime of Fig. 2, mice were treated with a single i.p. dose of α2,8 NANA-NP or PBS. We saw 
no alterations in lung, liver or kidney histology among groups. Furthermore, α2,8 NANA-NP did not alter 
serum LDH concentrations nor animal weights. Similarly no toxic effects were observed after weekly i.p. 
administration of α2,8 NANA-NP over 28 days, or in a bolus localized pulmonary delivery model (Fig. 
S5).  
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α2,8 NANA-NP elicit anti-inflammatory effects in human cell and whole lung ex vivo perfusion 
models. 
The translational potential of the nanoparticle was next explored in human models. Siglec-7 and -9 are the 
human orthologs of murine Siglec-E and represent translational targets for α2,8 NANA-NP. Flow 
cytometry analyses revealed that both receptors were present on primary human monocyte-derived 
macrophages (MDM) (Fig. 6A) and monocytes (Fig. 6F). Treatment of MDM with α2,8 NANA-NP 
significantly attenuated LPS-induced secretion of pro-inflammatory TNF-α (Fig. 6B), IL-6 (Fig. 6C) and 
IL-8 (Fig. 6D), and further enhanced levels of the anti-inflammatory cytokine IL-10 (Fig. 6E). 
Furthermore, α2,8 NANA-NP were also shown to limit the activation of NFκΒ through preventing the 
degradation of IκΒ (Fig. S6). Comparable results were observed with primary human monocytes and, 
although the degree of pro-inflammatory cytokine inhibition was less pronounced in comparison to MDM, 
TNF-α was nevertheless significantly attenuated (Fig. 6G, 6H and 6I). To assess possible toxicity, we 
examined IL-1β secretions in human MDM. Analogous to PBS controls, α2,8 NANA-NP did not induce 
IL-1β production (Fig. S5).  
 
We next investigated the feasibility of this treatment in attenuating inflammation in a human ex vivo lung 
perfusion (EVLP) model (Fig. S7) (32-34). Injury was induced through intrabronchial instillation of LPS 
and α2,8 NANA-NP or saline control treatment were added to the perfusate to model systemic 
administration in a randomized blinded manner. Pulmonary edema, the hallmark of ARDS, was measured 
via tissue wet/dry ratios (Fig. 6J), and BAL fluid IL-10 was also analysed (Fig. S6). Compared to controls, 
treatment with α2,8 NANA-NP induced a significant reduction in these wet/dry ratios. 
 
Discussion:  
Previously we have demonstrated that multivalent display of antibodies on the surface of nanoparticles 
can facilitate targeting to a given cell type and also elicits receptor clustering and activation, triggering 
downstream responses that are not achievable with free antibody (16, 35-38). In this current study, we 
devised an alternative strategy to induce specific Siglec activation and produce therapeutic effects. In lieu 
of antibodies, we employed a physiological ligand of mouse Siglec-E and its human equivalents (39). We 
demonstrated that α2,8-linked disialic acid elicited anti-inflammatory effects only when coated onto 
PLGA nanoparticles. We then showed that these nanoparticles produced therapeutically useful anti-
inflammatory effects in a range of murine and human inflammatory models.  
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Boyd et al (11) showed that activated Siglec-E recruited SHP phosphatases in order to ameliorate LPS-
induced signaling through reduction of IL-6 and TNF-α secretions. The downstream effects of this 
nanoparticle engagement in both murine and human model systems were in agreement with the previously 
reported findings. We showed that α2,8 NANA-NP can specifically target Siglec-E and reduce 
inflammatory cytokine production in models of systemic inflammation and localized lung injury. 
McMillan et al (10) reported that lung neutrophilia was exacerbated in a murine model of ARDS in a 
Siglec-E deficient background. Similarly, we found that nanoparticle-mediated activation of Siglec-E 
attenuated pulmonary neutrophil counts. 
 
In response to reports verifying the expression of Siglec-E on other cell types such as neutrophils (10,39), 
we examined the cellular targets of α2,8 NANA-NP. Upon i.p. administration of fluorescent α2,8 NANA-
NP macrophages appeared to be the primary target, expressing higher levels of Siglec-E compared to 
neutrophils. The functionality of the nanoparticles appeared to be neutrophil-independent as the ability of 
these nanoparticles to rescue animals from lethal inflammation was attenuated following macrophage 
depletion. Hypothetically, in contrast to macrophages, α2,8 NANA-NP may be unable to cross-link 
Siglec-E on neutrophils to the extent needed for sufficient activation.  Recently, a newly described innate 
response activator B cell population was shown to play an important role in bacterial clearance and sepsis 
associated cytokine responses (40).  Our data suggest that macrophage populations are the predominant 
targeted cell population by α2,8 NANA-NP and are largely responsible for our observed anti-
inflammatory effectiveness, however, our experiments cannot completely exclude that our functionalized 
nanoparticles could directly or indirectly influence these newly described innate effector B cells. 
 
Our previous studies hypothesized that Siglec-E, and potentially other human equivalents, were 
upregulated in a negative feedback manner to return cells to homeostasis. While LPS was able to potently 
upregulate the expression of Siglec-E in mouse macrophages, this was not significant in human MDM, 
confirming other reports (41). While investigating this dichotomy, we noted that LPS could enhance IL-10 
production in both settings and this was further potentiated on co-treatment with α2,8 NANA-NP. Others 
have reported that LPS-induced IL-10 has an important role in attenuating pro-inflammatory responses 
and maintaining tolerance, and this thus highlights an important role for Siglecs in homeostatic and anti-
inflammatory responses (42).  
 
This alternative approach to targeting Siglec receptors extends the findings of Boyd et al (11). We report 
that IL-10 is fundamental for the downstream expression of Siglec-E after LPS stimulation. Moreover, we 
confirm our previous finding that this Siglec-E induction pathway is also MyD88 dependent. We propose 
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that this negative feedback pathway is exploited by α2,8 NANA-NP to block pro-inflammatory responses 
and enhance resolution (Fig. S7). In an inflammatory setting, α2,8 NANA-NP engages Siglec-E and 
potentiates inhibitory pathways, including recruitment of SHP-2 and NFκB p50 dimer translocation to the 
nucleus. Elevated production of IL-10 then leads to further Siglec-E expression, enhancing the available 
receptors for nanoparticle binding. Activation of Siglec-E by cross-linking nanoparticles potently induces 
further secretion of IL-10. Importantly, the restoration of normal immune cell function is possible owing 
to the biocompatible and biodegradable nature of this PLGA platform. 
 
The consequences of Siglec-E activation observed here with our nanoparticle are consistent with an 
indirect approach to Siglec modulation using sialidase inhibitors to preserve Siglec-G signal transduction, 
inhibiting sepsis progression (43). Läubli et al (44) have recently described the inhibitory effects of 
Siglec-9 engagement on human neutrophils and macrophages with tumor expressed sialic acid. Other data 
show the strategies evolved by bacteria and viruses to evade immunosurveillance mechanisms (45, 46) 
and enhance dissemination and survival. Interestingly, a variety of sialic acid-bearing ‘nanocarriers’ have 
been described before. For instance, different sialic acid variants have been exploited to selectively deliver 
chemotherapeutics to B cells or to enhance nano-surface hydrophilicity, thus improving bioavailability 
(47-50). In another report, liposomes decorated with high affinity Siglec-7 ligands enabled efficient 
delivery of mycobacterial ligands to dendritic cells, resulting in a robust T cell immune response (51). 
Similarly, a liposomal formulation was designed to target macrophage-expressed sialoadhesin, which also 
elicited T cell activation (52).   
 
In conclusion, we have developed a Siglec-targeting approach that is distinct from other reported 
strategies. Here we have shown that nanoparticle surface display of sialic acid promotes oligomerization 
and activation of Siglecs on macrophages.  We have been able to exploit this effect to elicit therapeutically 
useful effects in murine models of systemic and pulmonary inflammation.  Crucially, we have 
demonstrated the translational potential of α2,8 NANA-NP in human assays, including an EVLP model, 
which currently represents the most advanced pre-clinical model for lung-targeting therapeutics.  Taken 
together our findings validate this nanotherapeutic approach, and confirm Siglecs as drugable anti-
inflammatory targets.  
 
Materials and Methods: 
Mice: C57BL/6 specific pathogen free WT mice were purchased from Harlan Laboratories (UK) and used 
at 6-8 weeks. IL-10-/- (C57BL/6 Background) mice were a kind gift of the MGC Foundation (53). All 
experiments were sanctioned by the UK Home Office and approved by Queen’s University Belfast Ethical 
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Review Committee or Irish Department of Health and Children and Trinity College Dublin Bioresources 
Ethical Review Board.   
Cell preparation and culture: Peritoneal macrophages were collected through injection of sterile PBS into 
the peritoneal cavity of WT mice. Cells were lavaged and washed once with PBS prior to counting and 
adherence to culture plates for 2hr. Non-adherent cells were discarded, whilst adherent cells were 
collected by vigorous washing and characterized as macrophages by FACS as CD11b+F4/80+ cells. The 
murine macrophage RAW 264.7 cell line was obtained from the American Type Culture Collection and 
immortalised WT or MyD88-/- murine BMDM were a kind gift from Prof. Andrew Bowie (Trinity College 
Dublin). The above cells were cultured in DMEM supplemented with 10% low-endotoxin foetal calf 
serum, 1% penicillin/streptomycin and 1% L-glutamine (subsequently referred to as complete DMEM) 
(PAA) during stimulations at 37°C, 5% CO2. Primary murine BMDM were prepared from C57BL/6 WT 
mice and cultured for one week in complete DMEM. Differentiation was driven by granulocyte 
macrophage-colony stimulating factor (GM-CSF) derived from L929 supernatant. Human monocytes 
were isolated from healthy donor buffy coats by centrifugation across a Ficoll-Paque gradient (GE 
Healthcare), followed by adherence purification. Cells were matured in RPMI supplemented with 10% 
low-endotoxin foetal calf serum, 1% penicillin/streptomycin and 1% L-glutamine. Differentiation of 
monocytes to macrophages was achieved through the addition of 10ng/mL GM-CSF (Peprotech) to the 
culture media for seven days. 
Study design: 
The hypothesis of this investigation was that PLGA nanoparticles coated with a sialic acid ligand would 
inhibit inflammatory responses of macrophages and monocytes by binding to their cognate Siglec receptor 
on the cell surface. Investigations were designed to evaluate the impact of sialic acid coated nanoparticles 
compared to uncoated nanoparticle and ligand controls. This hypothesis was tested in various human and 
murine models of inflammation and experimental replication is defined within the appropriate figure 
legends. In vivo studies were carried out on littermate animals to minimise variances between groups. The 
number of animals within each study arm is denoted within the appropriate figure legends. Ethical 
approval for the use of buffy coat residue from anonymized healthy blood donors for monocyte isolation 
was obtained from the Northern Ireland Blood Transfusion Service. Experiments were repeated from 
multiple donors to minimize bias. Human lungs for the EVLP studies were obtained and used with 
approval from the International Institute for the Advancement of Medicine (IIAM). Ethical approval for 
the use of lungs and human donor blood in the EVLP model was obtained from Queen’s University 
Belfast School of Medicine, Dentistry and Biomedical Sciences School Research Ethics Committee. Both 
EVLP and CLP studies were conducted in a blinded manner. 
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Evaluation of the anti-inflammatory effects of α2,8 NANA-NP: Peritoneal macrophages were stimulated 
with 100ng/mL Escherichia coli R515 LPS (Invivogen) ± nanoparticles as specified in the appropriate 
figure legends. Murine BMDM were stimulated with 1ng/mL LPS overnight to upregulate Siglec-E. 
BMDM were washed twice in serum-free DMEM prior to resting for 2hr. BMDM were re-stimulated with 
100ng/mL LPS ± nanoparticles.  
Fluorescence Microscopy Imaging: RAW 264.7 cells were seeded on glass cover slips in six-well plates at 
2.5x105 cells per well and cultured overnight. Cells were stimulated for 3hr with 0.25µg/mL coumarin 6-
loaded nanoparticles in serum-free DMEM. Cells were washed three times with ice-cold PBS, fixed in 4% 
paraformaldehyde for 1hr and washed a further three times as above. Cells were incubated for 30min in 
HEPES buffer (0.1M; pH 8) and washed again as above. For nuclear staining, cells were incubated with a 
1:200 solution of TO-PRO-3 iodide (Invitrogen) and subsequently washed three times with ice-cold PBS. 
Cells were visualised by mounting coverslips onto microscope slides using Slow Fade Gold reagent 
(Invitrogen). Sample analyses were performed using confocal scanning laser microscopy (Leica Confocal 
TCS Sp2) with laser illumination at 488nm for green fluorescence, 543nm for red fluorescence and 633nm 
for far-red fluorescence. 
Attenuation of Siglec-E activity: Blocking of Siglec-E dependent binding was achieved by 2hr pre-
treatment of cells with 10µg/mL anti-Siglec-E (Antibodies-online) or IgG isotype (Fusion Antibodies), 
prior to stimulation with LPS, nanoparticles or controls. WT peritoneal macrophages were plated at 5x105 
cells/well in 24 well plates. Siglec-E gene silencing was accomplished by transfecting macrophages with 
genecellin nanoporters encapsulating 2µg of scrambled shRNA or Siglec-E specific shRNA (Origene)(11) 
for 48hr as per manufacturer’s instructions. Following transfection, macrophages were stimulated for 
another 24hr with 100ng/mL LPS ± 125µg/mL nanoparticles. 
Immunoblotting and evaluation of NFκB: Immunoprecipitation of Siglec-E (R&D Systems) and analyses 
of SHP-2 (Santa-Cruz) by western blot was performed as described previously (11) using lysates from 
LPS ± nanoparticle-treated C57BL/6 macrophages. γ Tubulin was probed as a loading control (Sigma 
Aldrich). Nuclear translocation of NFκB p50 and p65 subunits was assessed using the colorimetric NFκB 
p50/p65 EZ-TFA transcription factor assay (Millipore) according to the manufacturer’s instructions. 
Model of LPS-induced systemic inflammation: C57BL/6 WT or IL10-/- mice were treated with i.p. 
injections of 6mg/kg LPS ± nanoparticles or controls dispersed in PBS. Mice were monitored over 50hr as 
per UK Home Office guidelines. Mice were culled immediately at a humane end-point noted by loss of 
self-righting and insensitivity to touch. Serum was sampled from tail-vein bleeds at specified time-points 
and analyzed by ELISA. Serum was obtained by allowing blood to clot at room temperature for 30min 
prior to centrifugation at 14000g for 10min.  
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Model of LPS-induced acute lung inflammation: C57BL/6 WT mice were anaesthetized and suspended on 
an endotracheal intubation platform (Penn-Century). A LS-2-M laryngoscope (Penn-Century) was used to 
illuminate the trachea and a blunt 24G IV catheter (BD) was positioned between the vocal cords. A total 
volume of 50µL was instilled into the lungs via the catheter, containing 20µg LPS in PBS. At 2hr 
following LPS instillation, 2mg α2,8 NANA-NP or Nude-NP were injected i.p. Mice were then sacrificed 
24hr post-LPS instillation. To facilitate collection of BAL fluid, a blunt 23G needle was placed within a 
small opening in the upper trachea and secured in position with Mersilk suture (Ethicon). The lungs were 
lavaged with a total volume of 700µL ice-cold PBS, which was instilled in 350µL aliquots via the tracheal 
cannula, followed by gentle aspiration. BAL fluid was centrifuged at 425g for 10min at 4oC and the cell 
pellets were resuspended in 100µL ice-cold PBS. Total viable cell counts were conducted using a 
haemocytometer under trypan blue exclusion. Following collection of BAL fluid, lung lobes were 
homogenized in a TissueLyser LT (Qiagen) for 4min. Samples were centrifuged at 18000g for 15min at 
4oC and supernatant cytokine levels were quantified by ELISA. 
Cytocentrifugation, cell staining and differential counts: Approximately 1 x 105 cells from each BAL fluid 
sample were cytocentrifuged onto coated cytoslides (Shandon Thermo Scientific) for 5min. Following 
fixation in methanol for 20min, the slides were dried at room temperature and then stained in May-
Grünwald solution (VWR) for 8min. The cytospins were washed quickly in distilled water and submerged 
in Giemsa stain (VWR) for 8min. After two brief washes in PBS, the slides were dried at room 
temperature for 5min and a single drop of VectaMount™ AQ (Vector Laboratories) was added to each 
cytospin. Coverslips were then positioned and the slides were allowed to dry overnight. Representative 
images were captured at x40 magnification, using a DM5500B light microscope (Leica Microsystems) 
with Leica AL software (version 3.7). Differential counts were performed on a minimum of 400 white 
cells per cytospin.  
Flow cytometric analyses: Human monocytes and macrophages were stimulated as described in Fig. 6 
legend. Cells were stained with antibodies against Siglec-7-PE, Siglec-9-FITC or isotype controls (BD). In 
brief, cells were stained as per manufacturer’s instructions for 30min on ice. Cells were washed with 3mL 
FACS Buffer, centrifuged at 500g for 5min at 4oC and resuspended in 200µL FACS Buffer. Cells were 
analyzed using a FACSCantoII flow cytometer and FACSDiva (BD) and FLowJO software (Treestar). 
Representative plots shown. 
Depletion of macrophages using clodronate liposomes: Clodronate liposomes or control PBS liposomes 
were purchased from clodronateliposomes.org. In brief, 300µL of liposomes were injected i.p. into 
appropriate mice groups 48hr and 24hr prior to LPS and nanoparticle treatment. Mice were monitored for 
survival as above and serum was collected 24hr after treatment for analysis of TNF-α by ELISA. 
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Depletion of F4/80+ macrophages was assessed by flow cytometry as described previously to determine 
percentage of depletion (representative data to ~90% depletion shown in Fig. S3).  
Induction of CLP-mediated sepsis: Polymicrobial sepsis was induced in male C57BL/6 WT mice using 
the CLP method as described (25). Briefly, following anaesthesia, the caecum was ligated below the ileo-
caecal valve following midline laparotomy. Perforation of the caecum resulted in translocation of bacteria 
into the peritoneum and subsequent peritonitis. A defined severity of sepsis among animals was ensured 
with the uniform positioning of the ligation. Post-operative fluid resuscitation was provided with 1mL of 
sterile sodium chloride (37oC) administered subcutaneously. Groups of mice were given α2,8 NANA-NP 
or Nude-NP (2mg/mouse), equivalent free α2,8 NANA (30µg/mouse) or dexamethasone (0.1mg/mouse) 
i.p. 2hr post-surgery and every subsequent 24hr. Temperature transponders (Plexx B.V.) were implanted 
subcutaneously pre-surgery and temperature recorded electronically (DAS-6007, Bio Medic Data 
Systems) before and every 12hr post-surgery. Mice were scored every 12hr using the following criteria: 
score 0 – no symptoms; score 1 – piloerection, huddling; score 2 – piloerection, huddling, diarrhea; score 
3 – lack of interest in surroundings, severe diarrhea; score 4 – decreased movement, listless appearance; 
and score 5 – loss of self-righting reflex. When mice reached score 5 they were humanely killed. 
Analgesia was provided throughout to all mice using buprenorphine. 
Detection of secreted cytokines: DuoSet ELISA kits (R&D Systems) were used to detect concentrations of 
TNF-α, IL-6, IL-8, IL-10 and IL-1β within samples according to the manufacturer’s instructions. 
Real-time PCR: After appropriate stimulation, RNA was extracted using the RNeasy mini-kit (Qiagen). 
After conversion, 50ng first-strand cDNA was used in SYBR green reactions (Qiagen) using primers 
previously described (11). Siglec-E mRNA expression was analyzed and normalized to β-actin.  
Comparison of ΔΔCT values versus unstimulated levels was carried out using MxPRO QPCR Software 
(Version 4.10d) (Agilent technologies).  
EVLP model: EVLP setup and operation was as previously described (34). Briefly, lung injury was 
induced by intrabronchial instillation of 6mg LPS. Saline or 5mg α2,8 NANA-NP were added 
simultaneously to the perfusate, thereby modeling systemic delivery. At 4hr post-injury, BAL was 
performed and tissue sections were excised for determination of wet/dry ratios to evaluate accumulation of 
alveolar fluid, as a marker of global lung injury. Tissue sections were weighed immediately to obtain the 
wet weight, then dried in an oven at 56oC for 48hr and weighed again to determine the dry weight. 
Wet/dry ratios were calculated by dividing the wet weight by the dry weight. 
Statistical analysis: Student t-test was used to determine significance of parametric data between two 
groups. Mann-Whitney U test was used to determine significance of non-parametric data between two 
groups. One-way ANOVA and Tukey post-hoc test was used to determine significance of parametric data 
between multiple groups. Two-way ANOVA and Bonferroni post-hoc test was used to determine 
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significance of parametric data between WT and IL-10-/- mice strains. Survival significance was assessed 
with Kaplan-Meier plot and Log Rank Chi square test. Statistical significance was denoted by asterisks in 
the appropriate figures (defined as: *p<0.05; **p<0.01; ***p<0.001), in comparison to LPS only control 
unless indicated otherwise. Error bars represent ± 1 standard error of the mean ( ± SEM). 
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Figure Legends 
 
Fig. 1. α2,8 NANA-NP targets Siglec-E on macrophages to limit LPS-driven pro-inflammatory cytokine 
production in vitro. (A and B) C57BL/6 peritoneal macrophages were stimulated with 100ng/mL LPS ± 
125µg/mL α2,8 NANA-NP or appropriate controls for 12hr. Controls included α2,8 NANA alone (α2,8 
NANA; equivalent amount as attached to α2,8 NANA-NP surface), non-functionalized nanoparticles 
(Nude-NP; 125µg/mL) and nanoparticles displaying a control polysaccharide (Glucosamine NP; 
125µg/mL). Supernatants were assayed for TNF-α (Α) and IL-6 (B) by ELISA. Statistical significance 
was assessed by one way ANOVA with post-hoc Tukey test (***p<0.001, in comparison to LPS only). 
Data expressed as mean + SEM (n = 3 independent experiments in triplicate). (C) C57BL/6 peritoneal 
macrophages were stimulated with 100ng/mL LPS or media alone for 24hr. mRNA was extracted, 
converted to cDNA and analyzed by real-time PCR for Siglece gene expression. Data are expressed as 
fold change relative to untreated samples and normalized to β−actin gene expression. Data expressed as 
mean + SEM (n = 3 independent experiments in triplicate). (D and E) C57BL/6 peritoneal macrophages 
(D) or BMDM (E) were treated with the stated dose of LPS for 0, 12 and 24hr. Macrophages were lysed in 
RIPA prior to analysis of Siglec-E and γ Tubulin protein by Western blot (representative images of n = 4 
independent experiments). (F) C57BL/6 BMDM were stimulated with 1ng/mL LPS overnight to 
upregulate Siglec-E expression. Following 2hr pre-blocking with 10µg/mL anti-Siglec-E antibody, 
BMDM were stimulated with 100ng/mL LPS ± 125µg/mL α2,8 NANA-NP or Nude-NP for 12hr. 
Supernatants were assayed for TNF-α by ELISA. Statistical significance was assessed by one way 
ANOVA with post-hoc Tukey test (***p<0.001, in comparison to LPS only). Data expressed as mean + 
SEM (n = 3 independent experiments in triplicate). (G) C57BL/6 peritoneal macrophages were incubated 
with Siglec-E specific short hairpin RNA (shRNA) or scrambled shRNA encapsulated genecellin 
nanoporters for 48hr. Macrophages were then stimulated with 100ng/mL LPS ± 125µg/mL α2,8 NANA-
NP or Nude-NP for 24hr. Supernatants were assayed for TNF-α by ELISA. Statistical significance was 
assessed by one way ANOVA with post-hoc Tukey test (**p<0.01, in comparison to scrambled shRNA 
LPS only). Data expressed as mean + SEM (n = 3 independent experiments in triplicate). (H) Confocal 
fluorescence microscopy images of unstimulated RAW 264.7 cells (left panels) or RAW 264.7 cells 
incubated with 125µg/mL coumarin 6-loaded Nude-NP (green; middle panels) or coumarin 6-loaded α2,8 
NANA-NP (green; right panels) for 3hr. Nuclei were distinguished by To-Pro-3 staining (blue) 
(representative images of n = 3 independent experiments). (I) Confocal fluorescence microscopy images 
of RAW 264.7 cells incubated with 125µg/mL coumarin 6-loaded α2,8 NANA-NP (green; left panels). 
Alternatively RAW 264.7 cells were pre-incubated with control (IgG1; middle panels) or free anti-Siglec-
E (anti-Siglec-E; right panels) antibodies for 3hr and then incubated with coumarin 6-loaded α2,8 NANA-
23"
NP (green). Nuclei were distinguished by To-Pro-3 staining (blue) (representative images of n = 3 
independent experiments). 
 
Fig. 2. α2,8 NANA-NP attenuates systemic inflammation in murine models. (A) C57BL/6 mice (n = 8 per 
group) were treated with i.p. injections of 6mg/kg LPS in conjunction with 2mg α2,8 NANA-NP or Nude-
NP, or treated with 2mg α2,8 NANA-NP only. Survival was monitored for 50hr. Statistical significance 
was assessed by Kaplan-Meier Log Rank Chi square test (***p<0.001). (B and C) At 24hr post-injection, 
blood samples were taken from mice by tail vein puncture and serum was assayed for TNF-α (B) and IL-
10 (C) by ELISA. Statistical significance was assessed by one way ANOVA with post-hoc Tukey test 
(***p<0.001). Data expressed as mean + SEM. (D) C57BL/6 mice (n = 4 per group) were treated with i.p. 
injections of 6mg/kg LPS (or PBS for α2,8 NANA-NP only control). After 2hr, 2mg α2,8 NANA-NP or 
Nude-NP were injected i.p. Survival was monitored for 50hr. Statistical significance was assessed by 
Kaplan-Meier Log Rank Chi square test (**p<0.01). (E and F) At 24hr post-LPS injection, blood samples 
were taken from mice by tail vein puncture and serum was assayed for TNF-α (E) and IL-10 (F) by 
ELISA. Data expressed as mean + SEM. (G) C57BL/6 mice (n = 8 per group) were treated with i.p. 
injections of clodronate liposomes or PBS control liposomes at -48hr and -24hr. All groups were then 
treated with i.p. injections of 6mg/kg LPS in conjunction with 1mg α2,8 NANA-NP or Nude-NP. Survival 
was monitored for 50hr. Statistical significance was assessed by Kaplan-Meier Log Rank Chi square test 
(***p<0.001, between control liposome + α2,8 NANA-NP and control liposome + Nude-NP groups). (H) 
CLP was performed on C57BL/6 mice (n = 8-10 per group), followed by i.p. injection of 2mg α2,8 
NANA-NP, 2mg Nude-NP, equivalent dosage of α2,8 NANA alone or 100µg dexamethasone 2hr after 
surgery and every 24hr subsequently. Survival was monitored for 9 days. Statistical significance was 
assessed by Kaplan-Meier Log Rank Chi square test (***p<0.001, between α2,8 NANA-NP and Nude-NP 
groups). (I) Clinical scoring post-CLP used the following criteria: score 0, no symptoms; score 1, 
piloerection, huddling; score 2, piloerection, huddling, diarrhea; score 3, lack of interest in surroundings, 
severe diarrhea; score 4, decreased movement, listless appearance; score 5, loss of self-righting reflex. 
Data expressed as mean ± SEM. (J) Body temperature post-CLP. Data expressed as mean ± SEM. 
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Fig. 3. α2,8 NANA-NP attenuates pulmonary inflammation in murine models. (A and B) C57BL/6 mice 
(n = 7-8 per group) were treated with 20µg LPS i.t. After 2hr, 2mg α2,8 NANA-NP or Nude-NP were 
injected i.p. Mice were sacrificed at 24hr post-LPS instillation, BAL fluid was collected and the lungs 
were then excised for further analyses. Neutrophil (A) and macrophage (B) counts in BAL fluid, as 
quantified from cytospin images. Statistical significance was assessed by Mann-Whitney U test 
(**p<0.01). Data expressed as mean + SEM. (C) Lung homogenate supernatants were assayed for IL-10 
by ELISA. Statistical significance was assessed by Mann-Whitney U test (*p<0.05). Data expressed as 
mean + SEM. (D) CLP was performed on C57BL/6 mice (n = 12-13 per group at outset of experiment), 
followed by i.t. instillation of 20µg α2,8 NANA-NP or Nude-NP 6-8hr after surgery. Clinical scoring 
post-CLP used the following criteria: score 0, no symptoms; score 1, piloerection, huddling; score 2, 
piloerection, huddling, diarrhea; score 3, lack of interest in surroundings, severe diarrhea; score 4, 
decreased movement, listless appearance; score 5, loss of self-righting reflex. Statistical significance was 
assessed by Student’s t-test (*p<0.05). Data expressed as mean ± SEM. (E) Survival was monitored for 
96hr. (F and G) CLP was performed on C57BL/6 mice (n = 7-11 per group), followed by treatment as 
described in (D). Mice were sacrificed at 30hr post-treatment and BAL fluid was collected. Total cell (F) 
and neutrophil (G) counts in BAL fluid. Statistical significance was assessed by Student’s t-test (*p<0.05). 
Data expressed as mean + SEM. 
 
Fig. 4. α2,8 NANA-NP induces SHP-2 recruitment to Siglec-E to promote downstream anti-inflammatory 
responses. (A) C57BL/6 peritoneal macrophages were pre-treated with 125µg/mL α2,8 NANA-NP or 
Nude-NP for 24hr prior to stimulation with 100ng/mL LPS for 0, 12 or 24hr. Macrophages were lysed in 
RIPA and immunoprecipitated (IP) using anti-Siglec-E antibody. IP was blotted for SHP-2, whilst whole 
cell lysate was blotted for Siglec-E and SHP-2 protein expression (representative image of n = 3 
independent experiments). (B) C57BL/6 peritoneal macrophages were treated with 125µg/mL α2,8 
NANA-NP or Nude-NP in conjunction with 100ng/mL LPS. Nuclear localization of p50 was determined 
using the p50/p65 EZ-TFA colorimetric assay. Data presented as fold ratio of p50/p65 compared to 
control untreated cells. Statistical significance was assessed by one way ANOVA with post-hoc Tukey test 
(**p<0.01). Data expressed as mean + SEM (n = 3 independent experiments in duplicate). (C) 
Immortalised wild-type (WT) or MyD88-deficient (MyD88-/-) BMDM were stimulated with 100ng/mL 
LPS ± 125µg/mL α2,8 NANA-NP for 24hr. Supernatants were assayed for IL-10 by ELISA. Statistical 
significance was assessed by two way ANOVA with post hoc Bonferroni test (*p<0.05). Data expressed 
as mean + SEM (n = 3 independent experiments in duplicate). (D) Immortalised WT or MyD88-/- BMDM 
were stimulated with 100ng/mL LPS or media alone for 24hr. Supernatants were assayed for IL-10 by 
25"
ELISA. Statistical significance was assessed by two way ANOVA with post hoc Bonferroni test 
(***p<0.001). Data expressed as mean + SEM (n = 3 independent experiments in duplicate).  
 
Fig. 5. Siglec-E is induced by IL-10 and the anti-inflammatory effects of α2,8 NANA-NP are IL-10 
dependent. (A) C57BL/6 peritoneal macrophages were stimulated with 100ng/mL LPS or 10ng/mL IL-10 
for 24hr. mRNA was extracted, converted to cDNA and analyzed by real-time PCR for Siglece gene 
expression. Data are expressed as fold change relative to untreated samples and normalized to β−actin 
gene expression. Data expressed as mean + SEM (n = 3 independent experiments in triplicate). (B) 
C57BL/6 peritoneal macrophages were stimulated as in (A). Macrophages were lysed in RIPA prior to 
analysis of Siglec-E and γ Tubulin protein expression by Western blot (representative image of n = 3 
independent experiments). (C) C57BL/6 peritoneal macrophages were pre-treated with 10 µg/mL IL-10 
receptor blocking antibody or IgG1 isotype control overnight. Macrophages were then stimulated with 100 
ng/mL LPS or 10 ng/mL IL-10 for 24hr. Macrophages were lysed in RIPA prior to analysis of Siglec-E 
and γ Tubulin protein expression by Western blot (representative image of n = 3 independent 
experiments). (D) C57BL/6 WT or IL-10-/- mice (n = 8 per group) were treated with i.p. injections of 
6mg/kg LPS in conjunction with 1mg α2,8 NANA-NP or Nude-NP. Survival was monitored for 50 hr. 
Statistical significance was assessed by Kaplan-Meier Log Rank Chi square test (**p<0.01 between WT + 
α2,8 NANA-NP and WT + Nude-NP groups). (E) At 12hr post-injection, blood samples were taken from 
mice by tail vein puncture and serum was assayed for TNF-α by ELISA. Statistical significance was 
assessed by two way ANOVA with post hoc Bonferroni test (***p<0.001 between WT + α2,8 NANA-NP 
and WT + Nude-NP groups). Data expressed as mean + SEM. 
 
Fig. 6. α2,8 NANA-NP promotes anti-inflammatory effects in human cell assays. (A) Primary human 
MDM (n = 4 donors) were stimulated with 500ng/mL LPS for 18hr. MDM were stained with Siglec-7-PE 
and Siglec-9-FITC or appropriate isotype control antibodies and analyzed by flow cytometry. 
Representative plots shown. (B, C and D) Primary human MDM (n = 6-13 donors) were pre-treated with 
10ng/mL LPS for 1hr prior to addition of 25µg/mL α2,8 NANA-NP or Nude-NP for a further 12hr. 
Supernatants were assayed for TNF-α (B), IL-6 (C) and IL-8 (D) by ELISA. Data presented as % change 
in cytokine levels relative to MDM stimulated with LPS only. Statistical significance was assessed by 
Mann-Whitney U test (*p<0.05, ***p<0.001). Data expressed as mean ± SEM. (E) Primary human MDM 
(n = 3 donors) were stimulated with 10ng/mL LPS ± 50µg/mL α2,8 NANA-NP. Supernatants were 
assayed for IL-10 by ELISA. Data expressed as mean + SEM. (F) Primary human monocytes (n = 2 
donors) were stimulated with 10ng/mL LPS for 24hr. Monocytes were stained with Siglec-7-PE and 
Siglec-9-FITC or appropriate isotype control antibodies and analyzed by flow cytometry. Representative 
26"
plots shown. (G, H and I) Primary human monocytes (n = 7 donors) were stimulated with 10ng/mL LPS 
± 50µg/mL α2,8 NANA-NP or Nude-NP for 18hr. Supernatants were assayed for TNF-α (G), IL-6 (H) 
and IL-8 (I) by ELISA. Data presented as % change in cytokine levels relative to monocytes stimulated 
with LPS only. Statistical significance was assessed by Mann-Whitney U test (*p<0.05). Data expressed 
as mean ± SEM. (J) Human lungs (n = 3 per group) were injured ex vivo by intrabronchial instillation of 
6mg LPS. Lungs were treated simultaneously with saline or 5mg α2,8 NANA-NP, which were introduced 
into the perfusate in order to model systemic administration. At 4hr post-treatment, lung tissue sections 
were excised for assessment of the wet/dry ratio (*p<0.05). Data expressed as mean ± SEM. 
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Supplementary methods: 
 
Materials: PLGA (RG502H) was purchased from Evonik. Acetone, dichloromethane (DCM), poly(vinyl 
alcohol) (PVA; 87−89% hydrolyzed with a molecular weight of 13-23kDa), 2-(N-morpholino) 
ethanesulfonic acid (MES) hydrate, magnesium chloride hexahydrate (MgCl2•6H2O), N-
Hydroxysuccinimide (NHS), rhodamine 6G, coumarin 6, purpald, sodium periodate and  N-ethyl-N(3-
dimethylaminopropyl) carbodiimide hydrochloride (EDC) were obtained from Sigma Aldrich. Di(α2→8) 
N-acetylneuraminic acid (α2,8 NANA) was purchased from Nacalai Tesque.  
Preparation of PLGA nanoparticles: 20mg PLGA was dissolved in 300µL DCM and 500µL acetone and 
injected under moderate stirring into 3mL ice-cold solution containing 2.5% (w/v) PVA and 45% (w/v) 
MgCl2•6H2O in pH 5 MES buffer. Both phases were then sonicated for 90sec on ice. An additional 5mL 
2.5% (w/v) PVA in pH 5 MES buffer was added under moderate stirring. Samples were left stirring 
overnight to allow organic solvent evaporation. Nanoparticles were centrifuged at 100,000g for 10min at 
4°C and washed three times with pH 5 MES buffer. Nanoparticle pellets were resuspended at 5mg 
PLGA/mL in pH 5 MES buffer prior to activation and conjugation.  
Nanoparticle activation and conjugation: Nanoparticle surface activation was achieved through the 
addition of 100µL EDC (0.2M) and 100µL NHS (1.4M), both dissolved in pH 5 MES buffer, followed by 
incubation at room temperature for 1hr with moderate stirring. Nanoparticles were centrifuged at 100,000g 
for 10min at 4°C and resuspended at 1mg PLGA/mL in PBS. α2,8 NANA (100µg) was added to 1mL of 
activated nanoparticles and incubated at 4°C overnight. Finally, nanoparticles were centrifuged at 20,000g 
for 1hr at 10°C to remove excess, non-conjugated α2,8 NANA. Nanoparticle pellets were stored at -20°C 
and resuspended as required in the appropriate diluent. 
Purpald assay for quantification of surface α2,8 NANA: 50µL of residual nanoparticle conjugation 
supernatant was incubated with 50µL sodium periodate (16mM) for 20min at room temperature in 
darkness. 50µL purpald reagent (136mM) was added and incubated as above. A further 50µL sodium 
periodate (64mM) was added and incubated for 20min as above before measurement of absorbance at 
550nm and comparison with known standards of α2,8 NANA made up in Nude-NP supernatants.  
Nanoparticle characterization: For scanning electron microscopy, α2,8 NANA-NP were mounted onto 
aluminium stubs using double-sided adhesive tape, coated with gold (Polaron E5150, Quorum 
Technologies) and visualized (Jeol 6500 FEG scanning electron microscope). Nanoparticle size and zeta 
potential were measured by dynamic light scattering and laser Doppler anemometry, respectively 
(Zetasizer Nano ZS system, Malvern instruments). For hyperspectral analysis, α2,8 NANA-NP and Nude-
NP were adjusted to a concentration of 1mg/mL in distilled water. The samples were imaged using a 
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microscope fitted with the Cytoviva illumination setup (x100 magnification) and reflectance spectra were 
acquired in the wavelength range of 400-1,000nm at 2nm of spectral resolution. For 1H nuclear magnetic 
resonance (NMR), samples were resuspended at 1mg/mL in deuterated dimethyl sulfoxide and analyzed 
using a Bruker Ultrashield 300MHz NMR spectrometer.  
Binding of nanoparticles to Siglec-E recombinant protein: 1µg Siglec-E Fc recombinant protein (R&D 
Systems) was bound to Protein A/G agarose beads (Life technologies) and incubated ± 125µg/mL 
rhodamine 6G-loaded α2,8 NANA-NP or Nude-NP for 1hr. Beads were pelleted and washed by three 
centrifugations at 12,000g in 1mL PBS to remove non-bound nanoparticles. Binding of nanoparticles to 
Siglec-E Fc was measured by fluorescence at 560nm and expressed as fold-change in binding versus 
Siglec-E Fc alone. 
Flow cytometric analyses of nanoparticle binding to macrophages and neutrophils: Peritoneal exudate 
cells from C57BL/6 mice treated with 1mg/kg LPS for 24hr were extracted and treated with 125µg/mL 
rhodamine 6G-loaded α2,8 NANA-NP or Nude-NP for 30min. Cells were washed with 3mL FACS Buffer 
at 500g for 5min at 4oC. Cells were stained with antibodies against CD11b-APCcy7, F4/80-PEcy7, Ly6G-
PerCP (EBiosciences) and Siglec-E-APC (R&D Systems). Rhodamine positivity was detected on FL-2 
channel. In brief, cells were stained as per manufacturer’s instructions for 30min on ice. Cells were 
washed once in FACS Buffer as above and resuspended in 200µL FACS Buffer. Cells were analyzed 
using a FACSCantoII flow cytometer and FACS DIVA (BD) and FlowJo software (Treestar). 
Representative plots are shown.   
Histological analyses of lung, liver and kidney: Lungs, livers and kidneys were excised from three 
experimental conditions described in Fig. S5. Organs were fixed in 10% formalin prior to paraffin 
embedding. 6µm sections were stained using Harris haematoxylin and eosin (Fisher Scientific). In brief, 
slide sections were rinsed in two changes of clearene (Leica Biosystems) for 3min, rehydrated in 3min 
changes of ethanol (100%, 100%, 95%, 95% and 70%), followed by rinsing in distilled water for 5min. 
Sections were stained in haematoxylin for 6min and rinsed under tap water until clear. Slides were 
counterstained in eosin (30sec to 1min) and dehydrated through two changes of 95% ethanol, followed by 
two changes of 100% ethanol for 3min. Slide sections were rinsed in two changes of clearene for 3min 
and mounted with DPX mountant prior to imaging. Sections were imaged using a Leica DM5500 
microscope (x10 magnification). 
LDH quantification: Serum LDH levels were determined using commercially available kits (Roche or 
Sigma) in accordance with the manufacturer’s instructions. 
EVLP BAL fluid collection and processing: BAL fluid! was collected at baseline and 4hr after LPS 
instillation. After the lung was rewarmed to 36oC following perfusion and inflation of the lung, the right 
(RUL) or left (LUL) upper lobe was cannulated with a catheter and advanced until gentle resistance was 
!3!
encountered. Following instillation of 125mL of 0.9% sodium chloride containing 5% high purity bovine 
serum albumin (Sigma Aldrich) into the RUL or LUL, lavage fluid was aspirated and centrifuged at 1000g 
for 5min at 4oC. The acellular supernatants were stored at -80 oC.  
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Supplementary figure legends: 
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Fig. S1. Nanoparticle characterization 
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Fig. S1. Nanoparticle characterization. (A) Scanning electron microscopy image of freeze-dried 
nanoparticles. Scale bar = 100nm (representative image of n = 2 independent experiments). (B) 
Nanoparticle size and zeta potential were measured by dynamic light scattering and laser Doppler 
anemometry, respectively. Purpald assay was used to quantify the amount of α2,8 NANA on the 
nanoparticle surface. Data expressed as mean ± SD (n = 3 independent experiments). (C) Hyperspectral 
profiles of α2,8 NANA-NP and Nude-NP. α2,8 NANA-NP were associated with lower intensity scatter, 
whereas Nude-NP produced higher intensity scatter, indicating that the surface chemistries of α2,8 
NANA-NP and Nude-NP were distinct from each other (n = 1 experiment). (D) Schematic of example 
proposed conjugation showing α2,8 NANA attachment to PLGA through free hydroxyls and confirmation 
of α2,8 NANA surface functionality by 1H NMR (d6-DMSO) spectroscopy. The spectrum for PLGA alone 
is shown in the second panel. The peaks at 5.21ppm and 1.47ppm correspond to the CH and CH3 protons 
of the lactic acid monomer units, respectively. The peak at 4.90ppm relates to the CH2 protons of the 
glycolic acid monomer units. The spectrum for Nude-NP (including EDC and NHS) is displayed in the 
third panel. The spectrum for the final product is presented in the fourth panel, following attachment of 
α2,8 NANA to Nude-NP via EDC/NHS chemistry. The appearance of a signal at approximately 1.90ppm 
corresponds to the methyl protons of the acetamido group of α2,8 NANA, thus confirming successful 
attachment of the targeting ligand to PLGA. Washing the sample with PBS appears to remove EDC and 
surplus α2,8 NANA not attached to PLGA, whilst there is also a reduction in the amount of NHS in the 
final product. Specifically, the peak at 2.58ppm, corresponding to the CH2 protons of NHS, is more 
intense in the spectrum for Nude-NP. This peak is reduced by approximately 30% in the α2,8 NANA-NP 
spectrum (representative traces of three independent experiments). (Ε)  C57BL/6 peritoneal macrophages 
were stimulated with 100ng/mL LPS ± 125µg/mL of seven independent preparations of α2,8 NANA-NP 
for 24hr. Supernatants were assayed for TNF-α by ELISA (n = 1 experiment). (F)  C57BL/6 peritoneal 
macrophages were stimulated with 100ng/mL LPS ± 125µg/mL α2,8 NANA-NP conjugated with various 
amounts of α2,8 NANA or α2,8 NANA alone for 12hr. Supernatants were assayed for TNF-α by ELISA. 
Statistical significance was assessed by one way ANOVA with post-hoc Tukey test (*p<0.05, 
***p<0.001, in comparison to LPS only). Data expressed as mean + SEM (n = 3 independent experiments 
in triplicate). (G) C57BL/6 BMDM were stimulated with 100ng/mL LPS ± 125µg/mL α2,8 NANA-NP for 
0, 3, 6, 12 or 24hr. Supernatants were assayed for TNF-α by ELISA. Statistical significance was assessed 
by one way ANOVA with post-hoc Tukey test (**p<0.01, in comparison to 0hr). Data expressed as mean 
+ SEM (n = 3 independent experiments in triplicate). (H) C57BL/6 peritoneal macrophages were 
stimulated with 100ng/mL LPS ± 2-fold serial dilutions of α2,8 NANA-NP or Nude-NP, ranging from 
250µg/mL to 1.95µg/mL for 12hr. Supernatants were assayed for TNF-α by ELISA (n = 2 independent 
experiments in duplicate, with representative results from one experiment shown). 
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Fig. S2. α2,8 NANA-NP bind to Siglec-E and induce receptor clustering. (A) 1µg Siglec-E Fc was 
incubated with rhodamine 6G-loaded α2,8 NANA-NP or Nude-NP for 1hr. Binding of nanoparticles to 
Siglec-E Fc was measured by fluorescence and expressed as fold-change in binding versus Siglec-E Fc 
alone. Statistical significance was assessed by one way ANOVA with post-hoc Tukey test (***p<0.001). 
Data expressed as mean + SEM (n = 3 independent experiments in triplicate). (B) Confocal fluorescence 
microscopy images of RAW 264.7 cells treated with 125µg/mL rhodamine 6G-loaded α2,8 NANA-NP or 
Nude-NP (green) or 10µg/mL anti-Siglec-E antibody for 1hr. Cells were stained with anti-Siglec-E-APC 
(red) and ProLong Gold plus DAPI to visualize nuclei (blue). Arrows indicate clustering of Siglec-E 
(representative images of n = 2 independent experiments). 
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Fig. S3. Clodronate depletion of macrophages. C57BL/6 mice (n = 4 per group) were treated with PBS or 
clodronate liposomes 48hr and 24hr prior to extraction of peritoneal exudate. Cells were stained with 
F4/80-PEcy7 to discriminate macrophages and analyzed by flow cytometry. Representative histograms are 
shown. Bar graph represents percentage of macrophages present in clodronate group when compared to 
PBS liposome-treated controls. Data expressed as mean + SEM. 
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Fig. S4. Differential expression of Siglec-E and uptake of fluorescent α2,8 NANA-NP by macrophages 
and neutrophils. C57BL/6 peritoneal lavage cells were incubated with 125µg/mL rhodamine 6G-loaded 
α2,8 NANA-NP or Nude-NP for 30min. In addition to staining with Siglec-E-APC, cells were co-stained 
with CD11b-APCcy7 and F4/80-PEcy7 to discriminate macrophages or CD11b-APCcy7 and Ly6G-PerCP 
to discriminate neutrophils. Cells were analyzed by flow cytometry (representative plots of n = 2 
independent experiments). 
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Fig. S5. α2,8 NANA-NP exhibit no toxicity in preclinical models 
α2,8 NANA-NP PBS 
Li
ve
r 
Lu
ng
 
K
id
ne
y 
100 
150 
50 
0 
LD
H
 (m
U
/m
L)
 
α2,8 NANA-NP + - 
PBS + - 
α2,8 NANA-NP + - 
PBS + - 
0 
0.5 
1.5 
1.0 
R
el
at
iv
e 
w
ei
gh
t 
α2,8 NANA-NP PBS 
Li
ve
r 
Lu
ng
 
K
id
ne
y 
α2,8 NANA-NP PBS 
Li
ve
r 
Lu
ng
 
K
id
ne
y 
0 
20 
40 
LPS - + - 
IL
-1
β 
(p
g/
m
L)
 
2 
3 
1 
0 
LD
H
 (U
/m
L)
 
α2,8 NANA-NP + - 
PBS + - 
2 
3 
1 
0 
LD
H
 (U
/m
L)
 
α2,8 NANA-NP + - 
PBS + - 
α2,8 NANA-NP + - 
PBS + - 
0 
0.5 
1.5 
1.0 
R
el
at
iv
e 
w
ei
gh
t 
α2,8 NANA-NP + - 
PBS + - 
0 
0.5 
1.5 
1.0 
R
el
at
iv
e 
w
ei
gh
t 
α2,8 NANA-NP - 
PBS + 
+ - 
- - 
60 
!10!
Fig. S5. α2,8 NANA-NP exhibit no toxicity in preclinical models. Nanoparticle toxicity was assessed in 
different experimental designs. (A) C57BL/6 mice (n = 3 per group) were treated with a single i.p. 
injection of PBS or 2mg α2,8 NANA-NP. At 28 days post-treatment, the liver, lungs and kidneys were 
excised for histological analysis. Representative images of H&E stained organ sections are shown. (B) 
Blood was collected by cardiac puncture and serum LDH levels were determined. Data expressed as mean 
+ SEM. (C) Animal body weight was also assessed before and after treatment. Data presented as relative 
weight change post-treatment versus pre-treatment. Data expressed as mean + SEM. (D-F) In order to 
exclude toxicity and immune responses associated with repeated treatment regimes, C57BL/6 mice (n = 3 
per group) were treated with weekly i.p. injections of PBS or 2mg α2,8 NANA-NP. At day 28, toxicology 
analysis was performed as in (A-C). (G-I) C57BL/6 mice (n = 3-5 per group) were treated with PBS or 
1µg α2,8 NANA-NP i.t. At 24hr post-treatment, toxicology analysis was performed as in (A-C). (J) 
Primary human MDM (n = 3 donors) were stimulated with LPS or α2,8 NANA-NP. Supernatants were 
assayed for IL-1β by ELISA. Data expressed as mean + SEM. 
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Fig. S6. α2,8 NANA-NP prevent IκΒ degradation in THP-1 cells and enhance IL-10 production in 
the EVLP model. (A) THP-1 cells were stimulated with 100ng/mL LPS ± 125µg/mL α2,8 NANA-NP or 
Nude-NP for 0-90min. Cells were lysed in RIPA prior to analysis of IκB and γ Tubulin protein expression 
by Western blot (representative image of n = 3 independent experiments). (B) Human lungs (n = 3-4 per 
group) were injured ex vivo by intrabronchial instillation of 6mg LPS. Lungs were treated simultaneously 
with saline or 5mg α2,8 NANA-NP, which were introduced into the perfusate in order to model systemic 
administration. At 4hr post-treatment, BAL fluid was collected. BAL fluid supernatants were assayed for 
IL-10 by ELISA. Data expressed as mean ± SEM. 
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Fig. S7. Schematic of EVLP model and proposed mechanism of action of α2,8 NANA-NP. (A) Setup of 
EVLP model and associated treatment protocol. (B) Proposed anti-inflammatory action of α2,8 NANA-
NP (NP not drawn to exact scale). 
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